Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform

Immunai, a New York-based biotech company, today announced a $215M Series B, increasing the company’s total funding to date to $295M. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.

Join Our Mailing ListSign up to receive regular updates from our blog and news about Viola